Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: A substudy from the Antiretroviral Regimen Evaluation Study (ARES)

HIV Clinical Trials

Volumn 8, Issue 5, 2007, Pages 337-344

  Lowe, Selwyn H ^a,b,d   Hassink, Elly A M ^a   Van Eck Smit, Berthe L F ^b   Borleffs, Jan C C ^c   Lange, Joep M A ^a,b   Reiss, Peter ^a,b  

^a International Antiviral Therapy Evaluation Center   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DEXA scan; Didanosine; HAART; HIV; Lipoatrophy; Stavudine

Indexed keywords

DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE;

ADULT; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMB; LIPOATROPHY; MALE; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDANOSINE; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE;

EID: 36048956410     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0805-337     Document Type: Article

References (30)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
2. Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet. 2003;362:1758-1760.
3. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-131.
4. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
5. van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847-855.
6. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Ther. 2003;8:617-626.
7. Lichtenstein KA. Redefining lipodystrophy syndrome. Risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39:395-400.
8. Dube MP. HIV-associated lipoatrophy: what are the kinder, gentler agents? Clin Infect Dis. 2006;42:281-282.
9. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1 -infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447-2454.
10. van der Valk M, Casula M, Weverling GJ, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1 -infected patients randomly allocated to zidovudine-or stavudine-based therapy. Antiviral Ther. 2004;9:385-393.
11. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
12. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr. 2006;41:590-597.
13. Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretoviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. 2003;17:971-979.
14. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
15. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-215.
16. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48 week study of switching stavudine and/or protease inhibitors to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
17. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-270.
18. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
19. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
20. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficency virus-infected patients. Clin Infect Dis. 2002;34:649-657.
21. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147-155.
22. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14:37-49.
23. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180-189.
24. Lowe SH, Wensing AMJ, Hassink EAM, et al. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2005;6:235-245.
25. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 Recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296:827-843.
26. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents - A working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (October 10, 2006). Available at: http://AIDSinfo.nih.gov.
27. Gallant J, DeJesus E, Arribas JR, et al. Tenofovir Df, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
28. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2006 [Epub ahead of print].
29. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42:273-280.
30. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antiviral Ther. 2001;6:249-253.